TD Cowen analyst Yaron Werber has maintained their bullish stance on NKTX stock, giving a Buy rating on July 31.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Yaron Werber’s rating is based on several strategic factors that position Nkarta favorably in the biotech landscape. The company’s financial health is robust, with a cash runway extending into 2029, which provides a strong foundation for its ongoing and future clinical trials. This financial stability ensures that Nkarta can continue its research and development efforts without immediate funding concerns, allowing it to focus on achieving key clinical milestones.
Additionally, the modifications in the lymphodepletion protocols for the Ntrust-1 and Ntrust-2 trials, which now include an option for using both fludarabine and cyclophosphamide, are expected to enhance the efficacy and enrollment of these trials. This strategic flexibility could potentially lead to better outcomes and differentiate Nkarta’s NK cell therapy from existing CAR T cell therapies, particularly in terms of safety and convenience. The anticipated early data from these trials by the end of 2025, with more comprehensive results in 2026, further supports the potential for success in addressing unmet needs in autoimmune diseases.
In another report released on July 31, H.C. Wainwright also maintained a Buy rating on the stock with a $18.00 price target.